Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06854653 · ClinicalTrials.gov registry record · Phase 2

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

A Phase 2 study of CTCL, sponsored by Prescient Therapeutics.

Recruiting
Registry status
Phase 2
Development phase
115
Enrollment target
15
Study locations

NCT06854653 is a Phase 2 study of CTCL that is actively recruiting participants, run by Prescient Therapeutics. The registered enrollment target is 115 participants, above the 48-participant average among 4 other CTCL trials with a reported enrollment target (140% higher). The trial reports 15 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06854653, a Phase 2 study of CTCL, is actively recruiting participants, sponsored by Prescient Therapeutics.

RECRUITING
Registry status
Phase 2
Development phase
115 participants
Enrollment target
15
Study locations

Study Summary

This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 minutes on days 1 to 5 of a 14-day cycle for 4 cycles, then 21 day cycle thereafter. Subjects will be treated or followed up, if subjects discontinue treatment, for up to 18 months.

Conditions Studied

CTCL

Interventions

  • DRUG PTX-100

Study Locations (15)

California

  • City of Hope Comprehensive Cancer Cente - Duarte
  • University of California Irvine - Irvine

Connecticut

  • Yale Cancer Center - New Haven

Massachusetts

  • Dana-Farber Cancer Institute - Boston

New York

  • Rochester Skin Lymphoma Medical Group. PLLC - Rochester

Virginia

  • Virginia Commonwealth University Massey Comprehensive Cancer Cente - Richmond

New South Wales

  • Westmead Hospital - Westmead

Victoria

  • Epworth Healthcare - Melbourne

Western Australia

  • Linear Clinical Research - Nedlands

Trial Details

FieldValue
Enrollment Target 115 participants
Start Date 2025-03-28
Est. Completion 2028-06
Phase Phase 2

Sponsor

Prescient Therapeutics

6 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06854653

The ClinicalTrials.gov registry entry for NCT06854653 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 48-participant average among 4 other CTCL trials with a reported enrollment target (140% higher). The listed sponsor is Prescient Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with CTCL appearing as the primary indexed condition, and to 1 intervention - of which PTX-100 is the first listed.

NCT06854653 reports 15 study locations spanning 14 distinct geographic areas - top geographies include California, Connecticut, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06854653 about?

NCT06854653 is a clinical study titled "A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL". This is an open-label, phase 2 randomized study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). PTX-100 will be administered by IV infusion over 60 min...

What is the current status of trial NCT06854653?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2025-03-28. Estimated completion is 2028-06.

What conditions does trial NCT06854653 study?

This clinical trial studies the following conditions: CTCL.

What interventions are being tested in trial NCT06854653?

The interventions under investigation include: PTX-100 (DRUG).

Who is sponsoring clinical trial NCT06854653?

This trial is sponsored by Prescient Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06854653 being conducted?

This trial has 15 study locations across California, Connecticut, Massachusetts, New York, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for CTCL

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

CTCL

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.